{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T22:27:43Z","timestamp":1787783263101,"version":"build-2784847793"},"reference-count":23,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Ixekizumab, an IL-17A inhibitor, is an effective treatment for moderate-to-severe plaque psoriasis. Although clinical trials support the use of an induction phase for optimal results, real-world evidence comparing induction versus maintenance-only regimens is limited. Objectives: This study assessed the real-world effectiveness, safety, and drug survival of ixekizumab with and without an induction phase in patients with moderate-to-severe plaque psoriasis. Methods: A multicenter, observational study was conducted with 183 patients treated with ixekizumab over five years at tertiary hospitals in Andaluc\u00eda, Spain. Patients were divided into two groups: an induction group (160 mg at baseline, followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12, then every 4 weeks) and a non-induction group (80 mg every 4 weeks from initiation). Baseline characteristics, clinical outcomes (PASI [Psoriasis Activity Skin Index] and PGA [Physician Global Assessment] scores), and drug survival were analyzed. Results: The majority of patients were male (64.48% in the induction group, 58.74% in the non-induction group). No significant differences were found in age or BMI [body mass index] between groups. Baseline PASI and PGA scores were higher in the induction group, reflecting greater initial disease severity. Both regimens achieved significant clinical improvements, though the induction group demonstrated faster initial responses. Drug survival was lower in the induction group (p = 0.0033), potentially due to the higher baseline disease burden and severity in these patients. Comorbidities, including metabolic syndrome, cardiovascular risks, and psychiatric conditions, were prevalent, particularly in the induction group. Conclusions: Ixekizumab is effective for moderate-to-severe plaque psoriasis, with induction therapy yielding faster responses. However, lower drug survival in the induction group highlights the influence of initial disease severity on long-term outcomes. Real-world findings support the flexibility of ixekizumab across diverse patient populations, though further research is warranted.<\/jats:p>","DOI":"10.3390\/jcm14030833","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T08:57:48Z","timestamp":1738054668000},"page":"833","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative Analysis of Ixekizumab Effectiveness with and Without Induction Therapy in Moderate-to-Severe Psoriasis: A Real-World Study"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0381-6174","authenticated-orcid":false,"given":"Ricardo","family":"Ruiz-Villaverde","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hospital Universitario San Cecilio, Granada, Spain, Spain Biohealth Research Institute in Granada (ibs.GRANADA), 18006 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Jos\u00e9","family":"Ezomo-Gervilla","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario San Cecilio, Granada, Spain, Spain Biohealth Research Institute in Granada (ibs.GRANADA), 18006 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Molina-Espinosa","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario San Cecilio, Granada, Spain, Spain Biohealth Research Institute in Granada (ibs.GRANADA), 18006 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Gal\u00e1n-Gutierrez","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario San Reina Sof\u00eda, IMIBIC, 14004 C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Herrera-Acosta","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Virgen de la Victoria, 29010 M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Alonso","family":"Suarez-Perez","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Virgen de la Victoria, 29010 M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1046\/j.1365-2230.2001.00832.x","article-title":"Psoriasis\u2014Epidemiology and clinical spectrum","volume":"26","author":"Christophers","year":"2001","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/S0190-9622(03)01144-7","article-title":"Combining the new biologic agents with our current psoriasis armamentarium","volume":"49","author":"Lebwohl","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.det.2014.09.012","article-title":"Psoriasis: The Future","volume":"33","author":"Menter","year":"2015","journal-title":"Dermatol. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0733-8635(05)70376-4","article-title":"Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment","volume":"14","author":"Koo","year":"1996","journal-title":"Dermatol. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jaad.2005.10.008","article-title":"Quality-of-life issues in psoriasis and psoriatic arthritis: Outcome measures and therapies from a dermatological perspective","volume":"54","author":"Mease","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_6","first-page":"1842","article-title":"Comparison of disability and quality of life in rheumatoid and psoriatic arthritis","volume":"28","author":"Sokoll","year":"2001","journal-title":"J. Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"Menter","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaad.2010.11.055","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions","volume":"65","author":"Menter","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0001-7310(14)70015-8","article-title":"IL-17 and IL-17R: An auspicious therapeutic target for psoriatic disease","volume":"105","author":"Mitra","year":"2014","journal-title":"Actas Dermosifiliogr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s13555-016-0102-0","article-title":"Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials","volume":"6","author":"Farahnik","year":"2016","journal-title":"Dermatol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis","volume":"28","author":"Gordon","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40257-024-00845-4","article-title":"Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study","volume":"25","author":"Torres","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2246606","DOI":"10.1080\/09546634.2023.2246606","article-title":"Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: Results from an Italian retrospective cohort study (the LOTIXE study)","volume":"34","author":"Chiricozzi","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_14","first-page":"4060","article-title":"Long-term clinical efficacy and safety of ixekizumab for psoriatic patients: A single-center experience","volume":"27","author":"Burlando","year":"2023","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2160196","DOI":"10.1080\/09546634.2022.2160196","article-title":"Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: Literature review 2016\u20132021","volume":"34","author":"Reich","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/jdv.18376","article-title":"Comparative effectiveness of biologics in clinical practice: Week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO)","volume":"36","author":"Pinter","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e15608","DOI":"10.1111\/dth.15608","article-title":"Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: A 192 weeks multicentric retrospective study\u2014IL PSO (Italian landscape psoriasis)","volume":"35","author":"Malagoli","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis: A meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e14808","DOI":"10.1111\/dth.14808","article-title":"Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The corrona psoriasis registry","volume":"34","author":"Lockshin","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/ijd.14429","article-title":"Drug survival of biological therapy is showing class effect: Updated Results from slovenian national registry of psoriasis","volume":"58","author":"Lunder","year":"2019","journal-title":"Int. J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"adv00349","DOI":"10.2340\/00015555-3714","article-title":"Ixekizumab survival in heavily pretreated patients with psoriasis: A two-year single-Centre retrospective study","volume":"100","author":"Sherman","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1341708","DOI":"10.3389\/fimmu.2023.1341708","article-title":"Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: A retrospective multicenter real-world experience on 5932 treatment courses\u2014IL PSO (Italian landscape psoriasis)","volume":"14","author":"Gargiulo","year":"2024","journal-title":"Front Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Avallone, G., Maronese, C.A., Murgia, G., Carrera, C.G., Mastorino, L., Roccuzzo, G., Dapavo, P., Alberti-Violetti, S., Quaglino, P., and Ribero, S. (2023). Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12041662"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/3\/833\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:37:01Z","timestamp":1759919821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/3\/833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["jcm14030833"],"URL":"https:\/\/doi.org\/10.3390\/jcm14030833","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]}}}